Pathological Glucose Levels Enhance Entry Factor Expression and Hepatic SARS ‐ CoV ‐2 Infection
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Guocheng Rao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Department of Biotherapy, Center for Diabetes and Metabolism Research, State Key Laboratory of Biotherapy…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Virus Internalization, Hyperglycemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postdoctoral Research Fund of West China Hospital, Sichuan University, National Science and Technology Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Accumulating clinical evidence suggests an intricate relationship between severe COVID‐19 and preexisting metabolic complications, which share some metabolic dysregulations, including hyperglycaemia, hyperinsulinaemia and hyperlipidaemia. However, the potential role of these metabolic risk factors in SARS‐CoV‐2 infection and entry factor expression remains unknown. Here we report the implication of hyperglycaemia in SARS‐CoV‐2 infection and therapy. Hyperglycaemia, instead of hyperinsulinaemia and hyperlipidaemia, can significantly induce the expression of SARS‐CoV‐2 entry factors ( Ace2 , Tmprss2 , Tmprss4 , Furin and Nrp1 ) in liver cells, but not in lung and pancreatic cells, which is attenuated by mTOR inhibition. Correspondingly, pathological glucose levels promote SARS‐CoV‐2 entry into cultured hepatocytes in pseudovirus cell systems. Conversely, representative glucose‐lowering drugs (metformin, dapagliflozin, sitagliptin and exenatide) are able to diminish the enhancement of entry factor expression and SARS‐CoV‐2 infection in cultured hepatocytes under pathological glucose conditions. Intriguingly, SARS‐CoV‐2 entry factors are increased in the livers of nonalcoholic fatty liver disease and diabetes patients. These results define hyperglycaemia as a key susceptibility factor for hepatic SARS‐CoV‐2 infection, and provide insights into the clinical application of glucose‐lowering therapies in COVID‐19 patients under comorbid hyperglycaemia conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Department of Biotherapy, Center for Diabetes and Metabolism Research, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu,…
- Department of Endocrinology and Metabolism, Gansu Provincial Hospital, Lanzhou, China.
- Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Xianghui Fu
Förderung
- Postdoctoral Research Fund of West China Hospital, Sichuan University
- National Science and Technology Major Project
- National Natural Science Foundation of China
- 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University
Zitieren
APA
Rao, G., Sang, X., Zhu, X., Zou, S., Zhang, Y., Cheng, W., Tian, Y., & Fu, X. (2025). Pathological Glucose Levels Enhance Entry Factor Expression and Hepatic SARS ‐ CoV ‐2 Infection. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70581
Vancouver
Rao G, Sang X, Zhu X, Zou S, Zhang Y, Cheng W, et al. Pathological Glucose Levels Enhance Entry Factor Expression and Hepatic SARS ‐ CoV ‐2 Infection. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70581
BibTeX
@article{Rao2025,
author = {Rao, Guocheng and Sang, Xiongbo and Zhu, Xinyue and Zou, Sailan and Zhang, Yanyan and Cheng, Wei and Tian, Yan and Fu, Xianghui},
title = {Pathological Glucose Levels Enhance Entry Factor Expression and Hepatic SARS ‐ CoV ‐2 Infection},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70581}
}
EUVIMED